Bristol-Myers Squibb Company NYSE:BMY Price, Chart, News & Insight

Bristol Myers Squibb Jumps 5% as Growth Portfolio Transition Gains Credibility

Bristol Myers Squibb shares are up 5% in trading on April 30, as a convincing Q1 2026 beat reassured investors that the company's transition away from legacy products is firmly on track.

Revenue came in at $11.49 billion, beating the $10.69 billion consensus by 7.4%, while adjusted EPS of $1.58 topped the $1.42 estimate by 11.1%. The driver was a clear and accelerating split between old and new: the Growth Portfolio, which now accounts for roughly 54% of total sales, delivered 12% revenue growth to $6.2 billion, led by Camzyos, Breyanzi and Reblozyl. International revenues rose 11%, contrasting with a 1% decline in US revenues, underscoring a shifting geographic mix as newer growth brands deliver double-digit gains worldwide. (Simply Wall St, IndexBox)

The legacy drag, while real, was anticipated. Legacy Portfolio revenues fell 6% to $5.3 billion as generic competition continued to erode older products, partly offset by a 16% rise in Eliquis worldwide sales to $4.1 billion. Non-GAAP EPS fell 12% year-on-year to $1.58, but management reaffirmed full-year guidance of $46 to $47.5 billion in revenue and $6.05 to $6.35 in non-GAAP EPS, noting that both metrics are trending toward the upper end of those ranges. (FinancialContent)

What is lifting the stock beyond the headline beat is the pipeline narrative. CEO Christopher Boerner pointed to multiple pivotal data readouts ahead, and the company has recently inked deals with Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics and Ajax Therapeutics, signaling aggressive expansion across oncology and beyond.

💬 🔗

WS Investor 04-30-26

Bristol Myers Squibb and Pfizer announced a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis (apixaban) directly to U.S. patients through the online platform, expanding access to the widely prescribed blood thinner.

Starting April 27, 2026, a 30-day supply of Eliquis will be available for $345, providing a lower-cost option for cash-paying patients and increasing pricing transparency. The move builds on earlier direct-to-patient initiatives aimed at improving affordability and access.

The companies said the partnership supports efforts to reduce barriers to essential medications, particularly for patients managing conditions such as atrial fibrillation and blood clots.
Business Wire

💬 🔗

The Investor 04-26-26

Bristol Myers Squibb announced the expansion of its “Standing in the Gaap” program to improve equitable care for patients with multiple myeloma, marking the initiative’s 10th anniversary.

As part of the expansion, the company is launching one of the largest U.S. surveys on multiple myeloma, engaging over 1,000 patients, caregivers, and healthcare providers to better understand persistent gaps in care. Developed with input from major patient advocacy groups, the survey aims to capture real-world experiences and identify barriers faced by underserved communities.

Originally launched in 2016 to address disparities affecting African American patients, the program has reached thousands through educational initiatives and built a large digital community. Bristol Myers Squibb said insights from the new survey will guide future programs, partnerships, and strategies to enhance access, education, and support across the multiple myeloma care ecosystem.
Business Wire

💬 🔗

European Investor 03-31-26

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026.

💬 🔗

Global Finance News 03-19-26

Bristol Myers Squibb announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma.

The study showed that the MeziKd regimen delivered a statistically significant and clinically meaningful improvement in progression-free survival compared with treatment using carfilzomib and dexamethasone alone. Safety outcomes were consistent with the known profile of the therapy, and patients will continue to be monitored for long-term survival and safety outcomes.

The results represent the first successful Phase 3 trial for mezigdomide and the second positive Phase 3 study within Bristol Myers Squibb’s CELMoD program, which is based on targeted protein degradation technology designed to treat difficult blood cancers. Data from the trial will be presented at a future medical conference and shared with regulatory authorities.
Source: Business Wire

💬 🔗

WS Investor 03-09-26

FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis treatment

The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s oral drug Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis.

Sotyktu is the first tyrosine kinase 2 (TYK2) inhibitor approved for this condition. The approval was based on results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, where significantly more patients receiving once-daily Sotyktu achieved an ACR20 response at week 16 compared with placebo.

The drug was previously approved in 2022 for moderate-to-severe plaque psoriasis. Bristol Myers Squibb said the new indication expands treatment options for patients with psoriatic disease affecting both joints and skin.
Business Wire

💬 🔗

The Investor 03-07-26

Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company.

The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026.

💬 🔗

The Investor 03-03-26

SystImmune, Inc. and Bristol Myers Squibb reported positive interim Phase III results for izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

In the China-based Phase III trial BL-B01D1-307 (NCT06382142), iza-bren met its dual primary endpoints of progression-free survival (PFS) and overall survival (OS) at a pre-specified interim analysis, demonstrating statistically significant and clinically meaningful improvements versus physician’s choice chemotherapy in patients whose disease progressed after prior taxane therapy.

Izalontamab brengitecan is an EGFR×HER3 bispecific antibody-drug conjugate (ADC). The study marks the third Phase III trial in which the therapy has achieved its primary endpoint(s) and represents the first bispecific ADC in a Phase III setting to report dual positive PFS and OS results in TNBC.

The companies said full data will be presented at an upcoming medical conference.

Source: Bristol Myers Squibb, Buiness Wire, February 26, 2026.

💬 🔗

The Investor 02-28-26

Bristol Myers Squibb (NYSE: BMY) reported positive top-line results from a registrational Phase 2 study evaluating Reblozyl (luspatercept) in adults with alpha (α)-thalassemia.

The ongoing ex-U.S. trial met primary endpoints in both non-transfusion-dependent (NTD) and transfusion-dependent (TD) cohorts. In NTD patients, Reblozyl demonstrated a statistically significant and clinically meaningful increase in hemoglobin levels. In TD patients, the treatment achieved a significant reduction in red blood cell transfusion burden. All key secondary endpoints were also met, and the safety profile was consistent with prior thalassemia studies.

The data will be presented at an upcoming medical congress and discussed with China’s Center for Drug Evaluation. Reblozyl is already approved in the U.S. for certain beta thalassemia and myelodysplastic syndromes indications.

Source: Business Wire, February 23, 2026.

💬 🔗

Global Finance News 02-24-26

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) for iberdomide in combination with daratumumab and dexamethasone (IberDd) for patients with relapsed or refractory multiple myeloma (RRMM).

The FDA granted Breakthrough Therapy Designation and Priority Review, assigning a PDUFA target action date of August 17, 2026. Iberdomide is an investigational cereblon E3 ligase modulator (CELMoD) agent and could become the first approved therapy in this novel class.

The NDA is based on data from the Phase 3 EXCALIBER-RRMM trial, which demonstrated favorable minimal residual disease (MRD) negativity rates in a planned analysis. The ongoing study is also evaluating progression-free survival (PFS), with dual primary endpoints of MRD negativity and PFS. Approximately 664 patients were randomized in Stage 2 to receive either IberDd or a comparator regimen of daratumumab, bortezomib and dexamethasone.

The FDA is reviewing the application under Project Orbis, enabling concurrent evaluation by regulatory authorities in multiple countries.

If approved, iberdomide would expand Bristol Myers Squibb’s targeted protein degradation portfolio and build on its established presence in multiple myeloma, where IMiD-based therapies have become standard of care.

Business Wire

💬 🔗

The Investor 02-17-26

NYSE:BMYFollow

NYSE:BMY